Click Here for 5% Off Your First Aladdin Purchase!

Veltuzumab (anti-CD20) - Primary antibody, specific to MS4A1, Human IgG1, Antibody of CD20 (membrane-spanning 4-domains; subfamily A; member 1)

  • Azide Free
  • Carrier Free
  • ExactAb™
  • Low Endotoxin
  • Recombinant
  • Validated
  • ≥95%(SDS-PAGE&SEC)
  • Lot by Lot
Features and benefits
  • Short Overview:

    Purity>95% (SDS-PAGE&SEC); Endotoxin Level<1.0EU/mg; Human IgG1; CHO; ELISA, FACS, Functional assay, Animal Model; Unconjugated

  • Species reactivity(Reacts with): Human
  • Isotype: Human IgG1
    Application:
  • Animal Model
  • ELISA
  • Flow Cytometry
  • Functional Assay
Item Number
Ab175698
Grouped product items
SKUSizeAvailabilityPrice Qty
Ab175698-100μg
100μg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$109.90
Ab175698-1mg
1mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$519.90
Ab175698-5mg
5mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$1,399.90
Ab175698-10mg
10mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$2,239.90

Purity>95% (SDS-PAGE&SEC); Endotoxin Level<1.0EU/mg; Human IgG1; CHO; ELISA, FACS, Functional assay, Animal Model; Unconjugated

Basic Description

Product NameVeltuzumab (anti-CD20) - Primary antibody, specific to MS4A1, Human IgG1
SynonymshA20;IMMU-106
Specifications & PurityExactAb™, Validated, Carrier Free, Low Endotoxin, Azide Free, Recombinant, ≥95%(SDS-PAGE&SEC), Lot by Lot
SpecificityMS4A1
ConjugationUnconjugated
GradeAzide Free, Carrier Free, ExactAb™, Low Endotoxin, Recombinant, Validated
Action TypeBINDING AGENT
Mechanism of actionAntibody of CD20 (membrane-spanning 4-domains; subfamily A; member 1)
Product Description

Veltuzumab (anti-CD20) is a humanized anti-CD20 monoclonal antibody. Veltuzumab (anti-CD20) can be used for the research of cancer including non-Hodgkin lymphoma (NHL).
Purity
>95% (SDS-PAGE&SEC)
Endotoxin Level
< 1.0EU/mg

Product Properties

IsotypeHuman IgG1
Light Chain Typekappa
SDS-PAGE145 kDa
Purification MethodProtein A purified
FormLiquid
ConcentrationLot by Lot
Storage TempStore at -80°C,Avoid repeated freezing and thawing
Shipped InIce chest + Ice pads
Stability And StorageStore at -80℃ for 24 months. Upon delivery aliquot. Avoid freeze/thaw cycle.
CAS728917-18-8

Associated Targets

MS4A1 Tclin B-lymphocyte antigen CD20 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

Certificates

Certificate of Analysis(COA)

Enter Lot Number to search for COA:

To view the certificate results,please click on a Lot number.For Lot numbers from past orders,please use our order status section

3 results found

Lot NumberCertificate TypeDateItem
ZJ24F0607175Certificate of AnalysisJun 21, 2024 Ab175698
ZJ24F0607174Certificate of AnalysisJun 21, 2024 Ab175698
ZJ24F0607173Certificate of AnalysisJun 21, 2024 Ab175698

Related Documents

References

1. Cragg MS, Walshe CA, Ivanov AO, Glennie MJ.  (2005)  The biology of CD20 and its potential as a target for mAb therapy..  Curr Dir Autoimmun,  (3): (140-74).  [PMID:15564720]
2. Goldenberg DM, Rossi EA, Stein R, Cardillo TM, Czuczman MS, Hernandez-Ilizaliturri FJ, Hansen HJ, Chang CH.  (2009)  Properties and structure-function relationships of veltuzumab (hA20), a humanized anti-CD20 monoclonal antibody..  Blood,  113  (5): (1062-70).  [PMID:18941114]
3. Kuijpers TW, Bende RJ, Baars PA, Grummels A, Derks IA, Dolman KM, Beaumont T, Tedder TF, van Noesel CJ, Eldering E et al..  (2010)  CD20 deficiency in humans results in impaired T cell-independent antibody responses..  J Clin Invest,  120  (1): (214-22).  [PMID:20038800]

Solution Calculators